

# CITATION REPORT

List of articles citing

Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension

DOI: 10.1016/j.jash.2008.05.005

Journal of the American Society of Hypertension, 2008, 2, 462-8.

**Source:** <https://exaly.com/paper-pdf/44140893/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
102	Successful blood pressure control with additive administration of eplerenone, an aldosterone receptor blocker, in a patient with bilateral renovascular hypertension treated with angioplasty. <b>2010</b> , 49, 2455-9		0
101	Papel de la MAPA en el manejo de la hipertensi3 arterial resistente. <b>2010</b> , 27, 34-40		
100	Recent advances in the treatment of hypertension. <b>2011</b> , 9, 729-44		13
99	Aldosteronism and resistant hypertension. <b>2011</b> , 2011, 837817		23
98	Drug therapy for resistant hypertension: simplifying the approach. <b>2011</b> , 13, 120-30		29
97	Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics. <b>2011</b> , 13, 644-8		54
96	The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism. <b>2011</b> , 9, 180		40
95	Prevalence of resistant hypertension in the United States, 2003-2008. <b>2011</b> , 57, 1076-80		558
94	What is new in the management of resistant hypertension?. <b>2011</b> , 8, 261-273		2
93	Chronic intrarenal insulin replacement reverses diabetes mellitus-induced natriuresis and diuresis. <b>2012</b> , 59, 421-30		11
92	Renal denervation: ultima ratio or standard in treatment-resistant hypertension. <b>2012</b> , 60, 596-606		76
91	Response to Letter to Regarding Article, Effects of Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension: Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase 2 Trial. <b>2012</b> , 125,		
90	Eplerenone for the treatment of cardiovascular disorders. <b>2012</b> , 10, 831-8		3
89	Primary aldosteronism: clinical lateralization and costs. <b>2012</b> , 97, 3450-2		15
88	Comment on ESH position paper: renal denervation--an interventional therapy of resistant hypertension. <b>2012</b> , 30, 2441-2; author reply 2443		3
87	Comment on ESH position paper. <b>2012</b> , 30, 2443		3
86	Hypertension: an immunologic disease?. <b>2012</b> , 30, 2440-1		4

85	Resistant hypertension and aldosterone: an update. <b>2012</b> , 28, 318-25	41
84	Safety of mineralocorticoid receptor antagonists in patients receiving hemodialysis. <b>2012</b> , 46, 889-94	22
83	A simplified mechanistic algorithm for treating resistant hypertension: efficacy in a retrospective study. <b>2012</b> , 14, 191-7	15
82	Discovery of novel oxazolidinedione derivatives as potent and selective mineralocorticoid receptor antagonists. <b>2013</b> , 23, 4388-92	14
81	Aldosterone contributes to elevated left ventricular mass in black boys. <b>2013</b> , 28, 655-60	11
80	Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension. <b>2013</b> , 15, 186-92	45
79	New drug therapies interfering with the renin-angiotensin-aldosterone system for resistant hypertension. <b>2013</b> , 14, 285-9	11
78	Clinical management of resistant hypertension: practical recommendations from the Italian Society of Hypertension (SIIA). <b>2013</b> , 20, 251-6	7
77	Aldosterone synthase inhibition in humans. <b>2013</b> , 28, 36-43	66
76	Hyperaldosteronism as a common cause of resistant hypertension. <b>2013</b> , 64, 233-47	70
75	Renal denervation: a potential new treatment for severe hypertension. <b>2013</b> , 36, 10-4	13
74	Apparent and true resistant hypertension: why not the same?. <i>Journal of the American Society of Hypertension</i> , <b>2013</b> , 7, 509-11	14
73	How can resistant hypertension be identified and prevented?. <b>2013</b> , 10, 293-6	7
72	Epidemiology, prognosis, and treatment of resistant hypertension. <b>2013</b> , 33, 1071-86	10
71	RAAS inhibitors and cardiovascular protection in large scale trials. <b>2013</b> , 27, 171-9	66
70	Can we use mineralocorticoid receptor blockade in diabetic patients with resistant hypertension? Yes we can! But it may be a double-edged sword. <b>2013</b> , 31, 1948-51	
69	Renal denervation in the management of resistant hypertension: current evidence and perspectives. <b>2013</b> , 22, 511-8	5
68	Mechanisms of renal NaCl retention in proteinuric disease. <b>2013</b> , 207, 536-45	36

67	Resistant hypertension. <b>2013</b> , 252-269	
66	Size of blood pressure reduction from renal denervation: insights from meta-analysis of antihypertensive drug trials of 4,121 patients with focus on trial design: the CONVERGE report. <b>2013</b> , 99, 1579-87	70
65	Determinants of blood pressure reduction by eplerenone in uncontrolled hypertension. <b>2013</b> , 31, 404-13	17
64	Management of patients with resistant hypertension: current treatment options. <b>2013</b> , 6, 139-51	20
63	Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine. <b>2013</b> , 6, 129-38	63
62	Effectiveness of the direct renin inhibitor, aliskiren, in patients with resistant hypertension. <b>2013</b> , 54, 88-92	9
61	Non-interventional management of resistant hypertension. <b>2014</b> , 6, 1080-90	4
60	[Mineralocorticoid receptor antagonists and therapeutic strategies of cardiovascular damage]. <b>2014</b> , 142, 61-71	2
59	Aldosterone to active renin ratio is associated with nocturnal blood pressure in obese and treated hypertensive patients: the Styrian Hypertension Study. <b>2014</b> , 16, 289-94	10
58	Primary aldosteronism in hypertensive patients: clinical implications and target therapy. <b>2014</b> , 44, 697-706	17
57	The velocity of home blood pressure reduction in response to low-dose eplerenone combined with other antihypertensive drugs determined by exponential decay function analysis. <b>2014</b> , 36, 83-91	2
56	A critical review of the evidence supporting aldosterone in the etiology and its blockade in the treatment of obesity-associated hypertension. <b>2014</b> , 28, 3-9	18
55	High-dose spironolactone changes renin and aldosterone levels in acutely decompensated heart failure. <b>2014</b> , 56, e463-e470	6
54	Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series. <b>2014</b> , 24, 1681-4	21
53	Comparison of agents that affect aldosterone action. <b>2014</b> , 34, 285-306	23
52	Effect of spironolactone in resistant arterial hypertension: a randomized, double-blind, placebo-controlled trial (ASPIRANT-EXT). <b>2014</b> , 93, e162	36
51	Iipertensione arteriosa: il ruolo dell'Internista. <b>2015</b> , 3, 1	
50	Reviving the use of aldosterone inhibitors in treating hypertension in obesity. <b>2015</b> , 309, R1065-7	6

49	CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats. <b>2015</b> , 769, 266-73	47
48	Effect of aldosterone antagonists on blood pressure in patients with resistant hypertension: a meta-analysis. <b>2015</b> , 29, 159-66	26
47	Pharmacological treatment of aldosterone excess. <b>2015</b> , 154, 120-33	22
46	The Effects of Aldosterone Antagonists in Patients With Resistant Hypertension: A Meta-Analysis of Randomized and Nonrandomized Studies. <b>2015</b> , 28, 1376-85	71
45	Personalizing the diuretic treatment of hypertension: the need for more clinical and research attention. <b>2015</b> , 17, 542	2
44	Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension. <b>2015</b> , 200, 8-11	11
43	Mineralocorticoids in the heart and vasculature: new insights for old hormones. <b>2015</b> , 55, 289-312	34
42	Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. <b>2015</b> , 65, 407-13	150
41	Resistant hypertension: medical management and alternative therapies. <b>2015</b> , 33, 75-87	7
40	Medication adherence and resistant hypertension. <b>2015</b> , 29, 213-8	32
39	Dose doubling, relative potency, and dose equivalence of potassium-sparing diuretics affecting blood pressure and serum potassium: systematic review and meta-analyses. <b>2016</b> , 34, 11-9	26
38	A validated stability-indicating ultra performance liquid chromatography method for the determination of potential process-related impurities in eplerenone. <b>2016</b> , 39, 2907-18	4
37	Aldosterone-Induced Vascular Remodeling and Endothelial Dysfunction Require Functional Angiotensin Type 1a Receptors. <b>2016</b> , 67, 897-905	34
36	New Evidence Supporting the Use of Mineralocorticoid Receptor Blockers in Drug-Resistant Hypertension. <b>2016</b> , 18, 34	22
35	Add-On Use of Eplerenone Is Effective for Lowering Home and Ambulatory Blood Pressure in Drug-Resistant Hypertension. <b>2016</b> , 18, 1250-1257	17
34	CS-3150, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, Shows Preventive and Therapeutic Effects On Renal Injury in Deoxycorticosterone Acetate/Salt-Induced Hypertensive Rats. <b>2016</b> , 358, 548-57	39
33	Managing hypertension in type 2 diabetes mellitus. <b>2016</b> , 30, 445-54	29
32	Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016. <b>2016</b> , 129, 661-6	24

31	Roles of Aldosterone Receptor Antagonists in Heart Failure, Hypertension, and Chronic Kidney Disease. <b>2016</b> , 12, 201-206	4
30	Role of Adding Spironolactone and Renal Denervation in True Resistant Hypertension: One-Year Outcomes of Randomized PRAGUE-15 Study. <b>2016</b> , 67, 397-403	60
29	Eplerenone for hypertension. <b>2017</b> , 2, CD008996	16
28	Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. <b>2017</b> , 35, 1093-1099	19
27	Resistant Hypertension: Mechanisms and Treatment. <b>2017</b> , 19, 56	20
26	A meta-analysis of add-on use of spironolactone in patients with resistant hypertension. <b>2017</b> , 233, 113-117	33
25	Use of Aldosterone Antagonists for Treatment of Uncontrolled Resistant Hypertension. <b>2017</b> , 30, 103-109	34
24	[What are the pharmacological options for treating resistant hypertension?]. <b>2017</b> , 34 Suppl 1, 25-28	
23	Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists. <b>2017</b> , 13, 403-411	14
22	Eplerenone-Resistant Salt-Sensitive Hypertension in Nedd4-2 C2 KO Mice. <b>2017</b> , 18,	6
21	A New Era of Renal Denervation Trials for Patients With Hypertension?. <b>2018</b> , 71, 615-618	
20	Diagnosis, Prevention, and Treatment of Hypertensive Emergency/Hypertensive Crisis/Refractory Hypertension. <b>2018</b> , 263-288	
19	Cardiology Consult Manual. <b>2018</b> ,	
18	Resistant Hypertension. <b>2018</b> , 398-408	0
17	Diuretics in Hypertension. <b>2018</b> , 211-221	1
16	Primary Aldosteronism: Practical Approach to Diagnosis and Management. <b>2018</b> , 138, 823-835	66
15	Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Men's Issue?. <b>2019</b> , 21, 22	11
14	Treatment of Resistant and Refractory Hypertension. <b>2019</b> , 124, 1061-1070	50

13	Real-World Strategies to Treat Hypertension Associated with Pediatric Obesity. <b>2019</b> , 21, 18	6
12	Hypertension. <b>2019</b> , 170, ITC65-ITC80	8
11	Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study). <b>2020</b> , 75, 51-58	43
10	Special Article - The management of resistant hypertension: A 2020 update. <b>2020</b> , 63, 662-670	2
9	Approach to Resistant Hypertension from Cardiology and Nephrology Standpoints: Tailoring Therapy. <b>2021</b> , 39, 377-387	1
8	Prevalence of Chronic Kidney Disease in Type 2 Diabetes: The Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study. <b>2021</b> , 43, 1558-1573	2
7	Sympathetic hyperactivity in patients with hypertension: pathogenesis and treatment. Part II. <b>2021</b> , 20, 2845	
6	Appraisal of the Clinical Trial Data on Renal Denervation for the Management of Resistant Hypertension. <b>2015</b> , 45-57	
5	Problem of resistant arterial hypertension in the family doctor practice. <b>2015</b> , 2015, 26-31	
4	Teaching Programmes. <b>2017</b> , 333-341	
3	Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes.	1
2	A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease.	0
1	Aldosterone Synthase Inhibitors and Dietary Interventions: A Combined Novel Approach for Prevention and Treatment of Cardiovascular Disease. <b>2023</b> ,	0